Krystal Biotech Q1 net income $0.9 million on first VYJUVEK sales of $45.3 million
Krystal Biotech reported its first quarter 2024 results, its first product revenue after the May 2023 FDA approval of VYJUVEK, with net product revenue of $45.3 million and net income of $0.9 million, or $0.03 per share. A year earlier the company posted a net loss of $45.3 million, or $1.76 per share. The company said it continues to expect $150 million to $175 million of non-GAAP R&D and SG&A expense for 2024.
Key points
- Net product revenue was $45.3 million for the quarter ended March 31, 2024, with gross margin of 95%.
- Net income was $0.9 million, or $0.03 per share, compared with a net loss of $45.3 million, or $1.76 per share, in the first quarter of 2023.
- Cash, cash equivalents and investments totaled $622.3 million on March 31, 2024.
- The company continues to anticipate $150 million to $175 million of 2024 non-GAAP combined R&D and SG&A expense, excluding stock-based compensation.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.